New hope for head and neck cancer: smart drug targets tumors, boosts immune system
NCT ID NCT07408063
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new drug, GSK5764227, that delivers chemotherapy directly to cancer cells, either alone or with an immunotherapy called dostarlimab. The study enrolls 30 people with recurrent or metastatic head and neck cancer. Researchers will analyze tumor samples and blood tests to find markers that predict response or resistance, aiming to personalize future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GSK5764227 (antibody drug conjugate) and dostarlimab (immunotherapy)
What this could lead to
If successful, this could identify which patients benefit most from this drug combination, potentially leading to more personalized treatment for head and neck cancer.
What could go wrong
This is a small, early-phase trial (30 people) focused on finding biomarkers, not proving a cure. The drugs may not work for many patients, and side effects from the chemotherapy-like payload are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••